Proton-Pump Inhibitors (PPI) Lawsuit
Proton-pump inhibitor heartburn drugs like Nexium, Prilosec, and Prevacid linked to kidney disease, stomach cancer, and other serious conditions with long-term use.
Last updated: March 6, 2026
What Is This Lawsuit About?
The proton-pump inhibitor (PPI) lawsuit involves over 11,322 pending cases consolidated in MDL 2789 in the District of New Jersey, alleging that manufacturers of widely used heartburn and acid reflux drugs failed to adequately warn patients about the serious risks of long-term use — particularly chronic kidney disease, acute kidney injury, and kidney failure.
Proton-pump inhibitors are among the most commonly used medications in the world. Brand names include Nexium, Prilosec, Prevacid, Protonix, Dexilant, and Aciphex, as well as widely available generic and over-the-counter versions. An estimated 15 million or more Americans use PPIs, and many use them for years or even decades — far longer than originally intended.
Beginning in 2016, landmark studies published in JAMA Internal Medicine and other major medical journals established that long-term PPI use is associated with significantly elevated risks of kidney damage, stomach cancer, bone fractures, and other serious conditions. Plaintiffs allege that drug manufacturers knew or should have known about these risks and failed to provide adequate warnings to patients and prescribing physicians.
If you or a loved one took a PPI and developed kidney disease, stomach cancer, or other serious complications, you may be eligible to file a claim. For information about similar pharmaceutical lawsuits, see the Ozempic stomach paralysis lawsuit. Note that the PPI litigation is separate from the Zantac (ranitidine) litigation, which involved a different drug class and suffered a significant Daubert setback when the court excluded plaintiffs' expert testimony on cancer causation.
Who Qualifies?
You may qualify for the PPI lawsuit if you regularly took a proton-pump inhibitor and subsequently developed kidney disease or another serious health condition. An experienced attorney can evaluate your specific case during a free consultation.
Do You Qualify for the PPI Lawsuit?
You may be eligible if the following apply to your situation:
- You took a proton-pump inhibitor (Nexium, Prilosec, Prevacid, Protonix, Dexilant, Aciphex, or their generics) regularly
- You used a PPI for an extended period (months to years of regular use)
- You were diagnosed with chronic kidney disease (CKD) after starting PPI use
- You experienced acute kidney injury, kidney failure, or required dialysis
- You were diagnosed with stomach cancer (gastric cancer) after long-term PPI use
- You suffered bone fractures (hip, wrist, or spine) that may be linked to PPI-related bone density loss
Which PPI Drugs Are Involved?
The litigation covers all major proton-pump inhibitors, including both prescription and over-the-counter formulations. If you took any of the following drugs and developed kidney damage or another qualifying condition, you may have a claim:
Products Named in This Lawsuit
Nexium (esomeprazole)
by AstraZeneca
Prescription and OTC. One of the best-selling drugs in history.
Prilosec / Prilosec OTC (omeprazole)
by AstraZeneca / Procter & Gamble
First PPI approved (1989). Widely available over-the-counter.
Prevacid (lansoprazole)
by Takeda Pharmaceuticals
Prescription and OTC. Available since 1995.
Protonix (pantoprazole)
by Pfizer
Prescription PPI. Commonly used in hospital settings.
Dexilant (dexlansoprazole)
by Takeda Pharmaceuticals
Dual delayed-release PPI. Prescription only.
Aciphex (rabeprazole)
by Eisai / Janssen
Prescription PPI. Less commonly prescribed.
Generic omeprazole, esomeprazole, lansoprazole, pantoprazole
by Various manufacturers
Store-brand and generic versions of all major PPIs are included in the litigation.
PPI Drugs Named in the Litigation
How PPIs Cause Kidney Damage
Research has identified several pathways through which long-term PPI use can damage the kidneys. Understanding these mechanisms is important because kidney damage from PPIs often develops gradually and without obvious symptoms until the condition is advanced.
PPI Kidney Damage Progression
Research indicates that PPI-induced kidney damage can occur through acute interstitial nephritis (an inflammatory reaction in the kidneys), gradual progression to chronic kidney disease through sustained low-level damage, and disruption of mineral absorption (particularly magnesium) that stresses kidney function over time. Many patients are unaware their kidneys are being affected until significant, potentially irreversible damage has occurred.
Took a PPI and Developed Kidney Problems?
Find out if you qualify for compensation. Free, no-obligation case review with an experienced pharmaceutical litigation attorney.
Lawsuit Timeline
The PPI litigation has been building since 2016 when major studies established the kidney damage connection. Here are the key milestones in this mass tort:
Lawsuit Timeline
First PPI Approved (Prilosec)
Omeprazole (Prilosec) becomes the first proton-pump inhibitor approved by the FDA, quickly becoming one of the most prescribed drug classes in America.
Nexium Launches
AstraZeneca launches esomeprazole (Nexium), which becomes one of the best-selling drugs in history. PPIs increasingly available over-the-counter.
First Bone Fracture Warnings
Studies begin linking long-term PPI use to increased bone fracture risk. FDA later adds fracture warnings to PPI labeling in 2010.
Landmark Kidney Study Published
Major studies published in JAMA Internal Medicine and the Journal of the American Society of Nephrology find that PPI users face a significantly higher risk of chronic kidney disease, acute kidney injury, and kidney failure.
MDL 2789 Created
The Judicial Panel on Multidistrict Litigation consolidates PPI kidney injury lawsuits into MDL 2789 in the District of New Jersey.
Stomach Cancer Studies Emerge
Research published in the journal Gut and other publications links long-term PPI use to increased stomach cancer risk, even after H. pylori eradication.
Cases Continue to Grow
The MDL caseload steadily grows as new plaintiffs file claims. Over 11,322 cases are pending as the litigation progresses through discovery and pre-trial proceedings.
Bellwether Selection Underway
Bellwether trial cases are being selected and prepared, which will set the stage for potential global settlement negotiations.
Settlement Amounts & Projections
No global PPI settlement has been reached yet as of March 2026. However, with over 11,322 cases pending and bellwether trials being prepared, legal analysts project the following potential settlement ranges based on the severity of kidney injuries:
Estimated Settlement Ranges
These are projected ranges based on the severity of kidney injuries and comparable pharmaceutical mass tort settlements. No PPI global settlement has been reached as of March 2026. Individual results will vary.
Settlement amounts will be influenced by factors including the specific kidney diagnosis (acute injury vs. chronic disease vs. failure), the duration and type of PPI used, the patient's age and overall health, and whether the manufacturer's labeling was adequate at the time of use. For more on how settlements are calculated, see our guide on mass tort settlement amounts and how settlement funds are distributed.
How to File a Claim
Filing a PPI kidney damage claim involves several steps. An experienced mass tort attorney can guide you through the process at no upfront cost. Learn more about the overall process in our guide on how to join a mass tort lawsuit.
Steps to File Your PPI Lawsuit Claim
Gather Medical Records
Collect documentation of your PPI prescriptions (including duration and dosage), kidney diagnosis records, and any related lab results or imaging studies.
Consult a Mass Tort Attorney
Speak with an attorney experienced in pharmaceutical litigation. Consultations are free and carry no obligation.
Case Evaluation
Your attorney reviews your PPI usage history, the timeline of your kidney or other diagnosis, and the strength of the causal connection.
File Your Claim
Your attorney files a complaint against the manufacturer(s) of the PPI you used, which will be consolidated into MDL 2789 in the District of New Jersey.
Discovery & MDL Proceedings
The case proceeds through discovery in the consolidated MDL. Your legal team accesses internal company documents about safety data and marketing practices.
Resolution
Your case may resolve through bellwether trial verdicts or a negotiated settlement. You pay nothing unless you receive compensation — attorneys work on contingency.
Named Defendants
Multiple pharmaceutical companies are named as defendants in the PPI litigation, reflecting the fact that several major manufacturers make and market these widely used drugs:
Defendant Overview
AstraZeneca
Manufacturer of Nexium (esomeprazole) and Prilosec (omeprazole). Nexium was one of the best-selling drugs in history with peak annual sales exceeding $6 billion. NYSE: AZN.
Takeda Pharmaceuticals
Manufacturer of Prevacid (lansoprazole) and Dexilant (dexlansoprazole). Tokyo-based pharmaceutical company. TSE: 4502.
Pfizer Inc.
Manufacturer of Protonix (pantoprazole). Pfizer acquired the drug through its acquisition of Wyeth. NYSE: PFE.
Procter & Gamble
Marketed Prilosec OTC (over-the-counter omeprazole) to consumers. NYSE: PG.
Plaintiffs allege that these companies knew or should have known about the kidney damage risks associated with long-term PPI use but failed to update their drug labeling, continued to market PPIs for extended use, and did not adequately warn patients or prescribing physicians about the dangers.
Scientific & Medical Evidence
The connection between long-term PPI use and kidney damage is supported by a substantial body of peer-reviewed scientific research:
- JAMA Internal Medicine (2016): A large study of over 10,000 participants found that PPI users had a 20-50% higher risk of developing chronic kidney disease compared to non-users, even after adjusting for other risk factors.
- Journal of the American Society of Nephrology (2016): Research found that PPI users had a significantly elevated risk of acute kidney injury and chronic kidney disease, with risk increasing with duration of use.
- Kidney International (2017): Study confirmed the association between PPI use and progressive kidney function decline, noting that many patients progress from acute kidney injury to chronic kidney disease silently.
- Gut (2017-2018): Studies published in this leading gastroenterology journal linked long-term PPI use to a 2-4 times higher risk of stomach cancer, even after eradication of Helicobacter pylori infection.
- BMJ Open (2019): A systematic review and meta-analysis confirmed the association between PPI use and increased risk of chronic kidney disease, acute kidney injury, and end-stage renal disease.
- FDA Safety Communications (2010-2014): The FDA issued multiple safety communications about PPI risks, including bone fractures (2010), hypomagnesemia (2011), and Clostridium difficile infections (2012), establishing a pattern of emerging safety concerns.
The cumulative weight of this evidence forms the scientific foundation of the litigation. For information on how scientific evidence is evaluated in mass tort cases, see our guide on what is a bellwether trial and how mass tort lawsuits work.
Key Research Findings: PPI Risks
Proton-Pump Inhibitors (PPI) Lawsuit FAQ
Which PPI drugs are named in the lawsuit?
What health problems are linked to long-term PPI use?
How long do I need to have taken PPIs to qualify?
Can I still file a claim if I used over-the-counter PPIs?
What is the current status of the PPI MDL?
How much could a PPI lawsuit settlement be worth?
Do I have to stop taking my PPI to file a lawsuit?
Is the Zantac lawsuit related to the PPI lawsuit?
Legal Disclaimer
This is for informational purposes only and does not constitute legal advice. It does not create an attorney-client relationship. The information presented may not reflect the most current legal developments. Consult a qualified attorney in your jurisdiction for advice about your specific situation.
Free Case Review — See If You Qualify
No obligation. No upfront costs. Attorneys work on contingency — you pay nothing unless you win.
Related Lawsuits
PFAS Chemicals Lawsuit
PFAS contamination of drinking water across the United States has led to billions in settlements from 3M, DuPont, and other manufacturers.
Paraquat Lawsuit
Paraquat herbicide exposure has been linked to a significantly increased risk of developing Parkinson's disease.
Dupixent Lawsuit
Dupixent (dupilumab) for eczema and asthma linked to cutaneous T-cell lymphoma at 30x the rate of other medications. FDA flagged the risk in March 2025.